Related Experiment Videos
Summary
Bacillus Calmette-Guérin (BCG) immunotherapy is effective for bladder carcinoma in situ, achieving remission in 70-80% of patients. Further research is needed to optimize BCG dosage, maintenance therapy, and identify prognostic markers for complete remission.
Area of Science:
- Urology
- Oncology
- Immunotherapy
Background:
- Bacillus Calmette-Guérin (BCG) is the primary intravesical therapy for urinary bladder carcinoma in situ.
- Standard induction therapy involves six weekly BCG instillations, yielding complete remission in 70-80% of patients.
Purpose of the Study:
- To review the efficacy and side effects of BCG therapy for bladder carcinoma in situ.
- To discuss the optimal dosage, maintenance therapy, and prognostic factors for complete remission.
Main Methods:
- Literature review of BCG therapy for bladder carcinoma in situ.
- Analysis of treatment outcomes, including remission rates and side effects.
- Discussion of prognostic indicators for treatment response.
Main Results:
- Complete remission achieved in 70-80% of patients with six weekly BCG instillations.
- Recurrences primarily observed in the distal ureter and prostatic urethra.
- Local (cystitis) and systemic side effects occur in 60-80% of patients; severe toxicity in ~5%.
Conclusions:
- BCG is highly effective but requires further optimization regarding dose and maintenance.
- Identifying prognostic markers like urinary cytokines and immune cell infiltration may predict remission.
- Recurrence management may necessitate cystectomy in some patients.